Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection

doi:10.3748/wjg.v13.i45.6115

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2615)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

758

HTML

1699

Figures (1-3)

158

Sum=2615

Dec 7, 2007 (publication date) through Sep 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. Dec 7, 2007; 13(45): 6115-6118
Published online Dec 7, 2007. doi: 10.3748/wjg.v13.i45.6115

Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection

Long Sun, Huang-Yang Ye, Ying-Hong Zhang, Yong-Song Guan, Hua Wu

Long Sun, Hua Wu, Minnan PET Center, The First Hospital of Xiamen, Fujian Medical University, Xiamen 316003, Fujian Province, China

Huang-Yang Ye, Ying-Hong Zhang, Department of Oncology, The First Hospital of Xiamen, Fujian Medical University, Xiamen 316003, Fujian Province, China

Yong-Song Guan, State Key Laboratory of Biotherapy, West China Medical School, Sichuan University, Chengdu 610041, Sichuan Province, China

Author contributions: All authors contributed equally to the work.

Correspondence to: Hua Wu, Minnan PET Center, The First Hospital of Xiamen, Fujian Medical University, Xiamen 316003, Fujian Province, China. wuhua1025@163.com

Telephone: +86-592-2139527 Fax: +86-592-2139527

Received: July 31, 2007
Revised: September 5, 2007
Accepted: October 26, 2007
Published online: December 7, 2007

Abstract

We report a 55-year-old male who developed advanced hepatic metastasis and peritoneal carcinomatosis after resection of remnant gastric cancer resection 3 mo ago. The patient only received epidermal growth factor (EGF) receptor antibody (Cetuximab) plus recombinant human endostatin (Endostar). Anti-tumor activity was assessed by ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computer tomography (PET/CT) at baseline and then every 4 wk. The case illustrates that ¹⁸FDG-PET/CT could make an early prediction of the response to Cetuximab plus Endostar in such clinical situations. ¹⁸FDG-PET/CT is a useful molecular imaging modality to evaluate the biological response advanced hepatic metastasis and peritoneal carcinomatosis to Cetuximab plus Endostar in patients after remnant gastric cancer resection.

Keywords: Hepatic metastasis; Remnant gastric cancer; Cetuximab; Recombinant human endostatin; ¹⁸F-fluorodeoxyglucose; Positron emission tomography/computer tomography